Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines
Abstract Live-attenuated measles virus (MeV) has been extraordinarily effective in preventing measles infections and their often deadly sequelae, accompanied by remarkable safety and stability since their first licensing in 1963. The advent of recombinant DNA technologies, combined with systems to g...
| Main Authors: | , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
Nature Portfolio
2022-10-01
|
| 丛编: | npj Vaccines |
| 在线阅读: | https://doi.org/10.1038/s41541-022-00543-4 |